NCT02331680View on ClinicalTrials.gov

A Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration

PHASE2CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Chronic Renal Failure
Interventions
DRUG

OPC-41061

DRUG

OPC-41061

DRUG

Placebo

Trial Locations (4)

Unknown

Kanto

Kinki

Kyushu

Tōhoku

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

NCT02331680 - A Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration | Biotech Hunter | Biotech Hunter